Cancer Cell
Volume 20, Issue 4, 18 October 2011, Pages 423-425
Journal home page for Cancer Cell

Preview
Resistance to EGFR-Targeted Therapy: A Family Affair

https://doi.org/10.1016/j.ccr.2011.10.006Get rights and content
Under an Elsevier user license
open archive

The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

Cited by (0)